X

Trial Profile

A phase II study of intermittent Gleevec (imatinib mesylate) and weekly paclitaxel in patients aged 70 or older with advanced non-small cell lung cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Apr 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imatinib (Primary) ; Paclitaxel (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use

Most Recent Events

02 Jul 2015 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
24 Jul 2012 Status changed from `active, no longer recruiting' to `discontinued' as reported by ClinicalTrials.gov.
20 Oct 2011 Planned End Date changed from 1 Aug 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov (NCT01011075).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com